Integration of biomarkers and clinical characteristics provides the best method for identifying patients with MODY

Integration of biomarkers and clinical characteristics provides the best method for identifying patients with MODY

Bibliographic Details
Main Authors:	Shields, B, McDonald, T, Owen, K, Malecki, M, Besser, R, Jones, A, Ellard, S, Hattersley, A
Format:	Journal article
Published:	2012

Similar Items

High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
by: McDonald, T, et al.
Published: (2011)

High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
by: McDonald, T, et al.
Published: (2011)

Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes.
by: McDonald, T, et al.
Published: (2012)

Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860-1862.
by: McDonald, T, et al.
Published: (2011)

Cystatin C is not a good candidate biomarker for HNF1A-MODY.
by: Nowak, N, et al.
Published: (2013)

Cystatin C is not a good candidate biomarker for HNF1A-MODY
by: Nowak, N, et al.
Published: (2013)

Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment
by: S Schnyder, et al.
Published: (2005-06-01)

The previously reported T342P GCK missense variant is not a pathogenic mutation causing MODY.
by: Steele, A, et al.
Published: (2011)

The previously reported T342P GCK missense variant is not a pathogenic mutation causing MODY
by: Steele, A, et al.
Published: (2011)

Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years
by: Lynam, A, et al.
Published: (2019)

Asian MODY: are we missing an important diagnosis?
by: Porter, JR, et al.
Published: (2006)

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
by: Jones Angus G, et al.
Published: (2012-06-01)

Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY).
by: Thomson, K, et al.
Published: (2003)

Permanent neonatal diabetes caused by an in-frame deletion in the N-terminus of Kir6.2
by: Craig, T, et al.
Published: (2008)

Sequencing PDX1 (insulin promoter factor 1) in 1788 UK individuals found 5% had a low frequency coding variant, but these variants are not associated with Type 2 diabetes.
by: Edghill, E, et al.
Published: (2011)

Simultaneous pancreas and kidney transplantation (SPK) should be indicated for patients with maturity-onset diabetes of the young (MODY) and end-stage nephropathy
by: Eininger, A, et al.
Published: (2013)

Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.
by: Flanagan, SE, et al.
Published: (2006)

Permanent neonatal diabetes in an Asian infant.
by: Porter, JR, et al.
Published: (2005)

Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms.
by: Männikkö, R, et al.
Published: (2010)

The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes.
by: Owen, K, et al.
Published: (2009)

Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
by: Mughal, SA, et al.
Published: (2013)

Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
by: Lauren R. Rodgers, et al.
Published: (2021-08-01)

A conserved tryptophan at the membrane-water interface acts as a gatekeeper for Kir6.2/SUR1 channels and causes neonatal diabetes when mutated.
by: Männikkö, R, et al.
Published: (2011)

The time-course of post-stroke fatigue: A systematic review of longitudinal cohort studies
by: Owen McDonald, et al.
Published: (2023-06-01)

Identifying routine clinical predictors of non-adherence to second line therapies in Type 2 diabetes: a retrospective cohort analysis in a large primary care database
by: Shields, B, et al.
Published: (2019)

Mutations in HHEX are not a common cause of monogenic forms of beta cell dysfunction.
by: Minton, J, et al.
Published: (2007)

Mutations of the same conserved glutamate residue in NBD2 of the sulfonylurea receptor 1 subunit of the KATP channel can result in either hyperinsulinism or neonatal diabetes.
by: Männikkö, R, et al.
Published: (2011)

Extending criteria for genetic testing increases diagnosis of maturity-onset diabetes of the young
by: Thanabalasingham, G, et al.
Published: (2010)

HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study
by: Timothy J McDonald, et al.
Published: (2021-10-01)

Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes.
by: Gloyn, A, et al.
Published: (2002)

A large-scale association analysis of common variation of the HNF1alpha gene with type 2 diabetes in the U.K. Caucasian population.
by: Weedon, M, et al.
Published: (2005)

No evidence for linkage at candidate type 2 diabetes susceptibility loci on chromosomes 12 and 20 in United Kingdom Caucasians.
by: Frayling, T, et al.
Published: (2000)

The CEO : an interactive book /
by: 456242 Burke, Owen, et al.
Published: (2005)

The free bilamellar autograft (FBA) procedure: A comprehensive case series of an alternative surgical approach to reconstruction of large eyelid defects
by: Heather M. McDonald, et al.
Published: (2023-02-01)

Maturity-onset diabetes of the young caused by a balanced translocation where the 20q12 break point results in disruption upstream of the coding region of hepatocyte nuclear factor-4alpha (HNF4A) gene.
by: Gloyn, A, et al.
Published: (2002)

The role of the HNF4alpha enhancer in type 2 diabetes.
by: Mitchell, S, et al.
Published: (2002)

The role of the HNF4α enhancer in type 2 diabetes variants of the HNF4α enhancer are not a common cause of susceptibility to type 2 diabetes
by: Mitchell, S, et al.
Published: (2002)

Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
by: Thanabalasingham, G, et al.
Published: (2012)

Teaching the Best Possible Medication History
by: Morgan McDonald, et al.
Published: (2014-07-01)

Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel.
by: Gloyn, A, et al.
Published: (2004)